Discovery of BIIB068: A Selective, Potent, Reversible Bruton?s Tyrosine Kinase Inhibitor as an Orall

Ma, Bin; Bohnert, Tonika; Otipoby, Kevin L.; Tien, Eric; Arefayene, Million; Bai, Judy; Bajrami, Bekim; Bame, Eris; Chan, Timothy R.; Humora, Michael; MacPhee, J. Michael; Marcotte, Douglas; Mehta, Devangi; Metrick, Claire M.; Moniz, George; Polack, Evelyne; Poreci, Urjana; Prefontaine, Annick; Sheikh, Sarah; Schroeder, Patricia; Smirnakis, Karen; Zhang, Lei; Zheng, Fengmei; Hopkins, Brian T.

doi:10.1021/acs.jmedchem.0c00702

Title: Discovery of BIIB068: A Selective, Potent, Reversible Bruton?s Tyrosine Kinase Inhibitor as an Orall

Journal Article · Wed Jul 01 00:00:00 EDT 2020 · J. Med. Chem.

DOI:https://doi.org/10.1021/acs.jmedchem.0c00702· OSTI ID:1836743

Ma, Bin; Bohnert, Tonika; Otipoby, Kevin L.; Tien, Eric; Arefayene, Million; Bai, Judy; Bajrami, Bekim; Bame, Eris; Chan, Timothy R.; Humora, Michael; MacPhee, J. Michael; Marcotte, Douglas; Mehta, Devangi; Metrick, Claire M.; Moniz, George; Polack, Evelyne; Poreci, Urjana; Prefontaine, Annick; Sheikh, Sarah; Schroeder, Patricia more »

Cite

Export

Save

Research Organization:: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Organization:: DOE - Office Of Science; INDUSTRY

OSTI ID:: 1836743

Journal Information:: J. Med. Chem., Vol. 63, Issue (21)

Country of Publication:: United States

Language:: ENGLISH

References (56)

Targeting pathological B cell receptor signalling in lymphoid malignancies Young, Ryan M.; Staudt, Louis M. Nature Reviews Drug Discovery, Vol. 12, Issue 3 https://doi.org/10.1038/nrd3937	journal	March 2013
Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity Weber, Alexander N. R.; Bittner, Zsofia; Liu, Xiao Frontiers in Immunology, Vol. 8 https://doi.org/10.3389/fimmu.2017.01454	journal	November 2017
The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages de Weers, Michel; Verschuren, Martie C. M.; Kraakman, Margriet E. M. European Journal of Immunology, Vol. 23, Issue 12 https://doi.org/10.1002/eji.1830231210	journal	December 1993
X-Linked Agammaglobulinemia and Other Immunoglobulin Deficiencies Smith, C. I. Edvard; Islam, Khalid B.; Vorechovsky, Igor Immunological Reviews, Vol. 138, Issue 1 https://doi.org/10.1111/j.1600-065X.1994.tb00851.x	journal	April 1994
Analysis of Clinical Presentations of Bruton Disease: A Review of 20 Years of Accumulated Data from Pediatric Patients at Severance Hospital Chun, Jin-Kyong; Lee, Taek Jin; Song, Jae Woo Yonsei Medical Journal, Vol. 49, Issue 1 https://doi.org/10.3349/ymj.2008.49.1.28	journal	January 2008
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia Tsukada, Satoshi; Saffran, Douglas C.; Rawlings, David J. Cell, Vol. 72, Issue 2 https://doi.org/10.1016/0092-8674(93)90667-F	journal	January 1993
The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases Vetrie, David; Vořechovský, Igor; Sideras, Paschalis Nature, Vol. 361, Issue 6409 https://doi.org/10.1038/361226a0	journal	January 1993
Role of Bruton's tyrosine kinase in immunodeficiency Tsukada, Satoshi; Rawlings, David J.; Witte, Owen N. Current Opinion in Immunology, Vol. 6, Issue 4 https://doi.org/10.1016/0952-7915(94)90151-1	journal	August 1994
X-linked immunodeficient mice spontaneously produce lupus-related anti-RNA helicase A autoantibodies, but are resistant to pristane-induced lupus Satoh, M. International Immunology, Vol. 15, Issue 9 https://doi.org/10.1093/intimm/dxg110	journal	September 2003
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Honigberg, L. A.; Smith, A. M.; Sirisawad, M. Proceedings of the National Academy of Sciences, Vol. 107, Issue 29 https://doi.org/10.1073/pnas.1004594107	journal	July 2010
Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell–associated damage in IFNα-driven lupus nephritis Katewa, Arna; Wang, Yugang; Hackney, Jason A. JCI Insight, Vol. 2, Issue 7 https://doi.org/10.1172/jci.insight.90111	journal	April 2017
The Role of Tec Family Kinases in Myeloid Cells Schmidt, Uwe; Boucheron, Nicole; Unger, Bernd International Archives of Allergy and Immunology, Vol. 134, Issue 1 https://doi.org/10.1159/000078339	journal	January 2004
Inhibiting Bruton’s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury Florence, Jon M.; Krupa, Agnieszka; Booshehri, Laela M. American Journal of Physiology-Lung Cellular and Molecular Physiology, Vol. 315, Issue 1 https://doi.org/10.1152/ajplung.00047.2018	journal	July 2018
BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils Smiljkovic, D.; Blatt, K.; Stefanzl, G. Allergy, Vol. 72, Issue 11 https://doi.org/10.1111/all.13166	journal	April 2017
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function Ren, Li; Campbell, Amanda; Fang, Huiqing Journal of Biological Chemistry, Vol. 291, Issue 6 https://doi.org/10.1074/jbc.M115.687251	journal	February 2016
Ibrutinib and novel BTK inhibitors in clinical development Akinleye, Akintunde; Chen, Yamei; Mukhi, Nikhil Journal of Hematology & Oncology, Vol. 6, Issue 1 https://doi.org/10.1186/1756-8722-6-59	journal	January 2013
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review Liang, Chengyuan; Tian, Danni; Ren, Xiaodong European Journal of Medicinal Chemistry, Vol. 151 https://doi.org/10.1016/j.ejmech.2018.03.062	journal	May 2018
New therapies for systemic lupus erythematosus — past imperfect, future tense Murphy, Grainne; Isenberg, David A. Nature Reviews Rheumatology, Vol. 15, Issue 7 https://doi.org/10.1038/s41584-019-0235-5	journal	June 2019
Role of Bruton’s tyrosine kinase in B cells and malignancies Pal Singh, Simar; Dammeijer, Floris; Hendriks, Rudi W. Molecular Cancer, Vol. 17, Issue 1 https://doi.org/10.1186/s12943-018-0779-z	journal	February 2018
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor Wu, Jingjing; Zhang, Mingzhi; Liu, Delong Journal of Hematology & Oncology, Vol. 9, Issue 1 https://doi.org/10.1186/s13045-016-0250-9	journal	March 2016
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase Guo, Yunhang; Liu, Ye; Hu, Nan Journal of Medicinal Chemistry, Vol. 62, Issue 17 https://doi.org/10.1021/acs.jmedchem.9b00687	journal	August 2019
Second-generation inhibitors of Bruton tyrosine kinase Wu, Jingjing; Liu, Christina; Tsui, Stella T. Journal of Hematology & Oncology, Vol. 9, Issue 1 https://doi.org/10.1186/s13045-016-0313-y	journal	September 2016
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis Montalban, Xavier; Arnold, Douglas L.; Weber, Martin S. New England Journal of Medicine, Vol. 380, Issue 25 https://doi.org/10.1056/NEJMoa1901981	journal	June 2019
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib Kaur, Varinder; Swami, Arjun Annals of Hematology, Vol. 96, Issue 7 https://doi.org/10.1007/s00277-017-2973-2	journal	March 2017
Idiosyncratic Toxicity: A Convergence of Risk Factors Ulrich, Roger G. Annual Review of Medicine, Vol. 58, Issue 1 https://doi.org/10.1146/annurev.med.58.072905.160823	journal	February 2007
Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans Evans, Erica K.; Tester, Richland; Aslanian, Sharon Journal of Pharmacology and Experimental Therapeutics, Vol. 346, Issue 2 https://doi.org/10.1124/jpet.113.203489	journal	May 2013
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK) Watterson, Scott H.; Liu, Qingjie; Beaudoin Bertrand, Myra Journal of Medicinal Chemistry, Vol. 62, Issue 7 https://doi.org/10.1021/acs.jmedchem.9b00167	journal	March 2019
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases Caldwell, Richard D.; Qiu, Hui; Askew, Ben C. Journal of Medicinal Chemistry, Vol. 62, Issue 17 https://doi.org/10.1021/acs.jmedchem.9b00794	journal	August 2019
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers: A phase I study of PRN1008 Smith, Patrick F.; Krishnarajah, Janakan; Nunn, Philip A. British Journal of Clinical Pharmacology, Vol. 83, Issue 11 https://doi.org/10.1111/bcp.13351	journal	August 2017
Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018) Feng, Yifan; Duan, Weiming; Cu, Xiaochuan Expert Opinion on Therapeutic Patents, Vol. 29, Issue 4 https://doi.org/10.1080/13543776.2019.1594777	journal	March 2019
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase Angst, Daniela; Gessier, François; Janser, Philipp Journal of Medicinal Chemistry, Vol. 63, Issue 10 https://doi.org/10.1021/acs.jmedchem.9b01916	journal	February 2020
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development Crawford, James J.; Johnson, Adam R.; Misner, Dinah L. Journal of Medicinal Chemistry, Vol. 61, Issue 6 https://doi.org/10.1021/acs.jmedchem.7b01712	journal	February 2018
Discovery of 6-Fluoro-5-( R )-(3-( S )-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4 H )-yl)-2-methylphenyl)-2-( S )-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1 H -carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers Watterson, Scott H.; De Lucca, George V.; Shi, Qing Journal of Medicinal Chemistry, Vol. 59, Issue 19 https://doi.org/10.1021/acs.jmedchem.6b01088	journal	September 2016
Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton’s Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis Kawahata, Wataru; Asami, Tokiko; Kiyoi, Takao Journal of Medicinal Chemistry, Vol. 61, Issue 19 https://doi.org/10.1021/acs.jmedchem.8b01147	journal	September 2018
Op0025 Fenebrutinib Compared to Placebo and Adalimumab in Patients with Inadequate Response to Either Methotrexate Therapy or Prior tnf Therapy: Phase 2 Study Cohen, Stanley; Tuckwell, Katie; Katsumoto, Tamiko R. Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019, Oral Presentations https://doi.org/10.1136/annrheumdis-2019-eular.4469	conference	June 2019
Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis Chan, Phyllis; Yu, Jiajie; Chinn, Leslie Pharmaceutical Research, Vol. 37, Issue 2 https://doi.org/10.1007/s11095-019-2752-y	journal	January 2020
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study Schafer, Peter H.; Kivitz, Alan J.; Ma, Jianglin Rheumatology and Therapy, Vol. 7, Issue 1 https://doi.org/10.1007/s40744-019-00182-7	journal	November 2019
Sat0089 Safety and Efficacy of Ly3337641, a Bruton’S Tyrosine Kinase Inhibitor in Patients with Rheumatoid Arthritis: a Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study Genovese, Mark C.; Spindler, Alberto; Sagawa, Akira Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019, SATURDAY, 15 JUNE 2019 https://doi.org/10.1136/annrheumdis-2019-eular.2672	conference	June 2019
Optimization of novel reversible Bruton’s tyrosine kinase inhibitors identified using Tethering-fragment-based screens Hopkins, Brian T.; Bame, Eris; Bell, Noah Bioorganic & Medicinal Chemistry, Vol. 27, Issue 13 https://doi.org/10.1016/j.bmc.2019.05.021	journal	July 2019
Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling Bender, Andrew T.; Gardberg, Anna; Pereira, Albertina Molecular Pharmacology, Vol. 91, Issue 3 https://doi.org/10.1124/mol.116.107037	journal	January 2017
Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz Nature Chemical Biology, Vol. 7, Issue 1 https://doi.org/10.1038/nchembio.481	journal	November 2010
Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling Choi, Go-Wun; Lee, Yong-Bok; Cho, Hea-Young Pharmaceutics, Vol. 11, Issue 4 https://doi.org/10.3390/pharmaceutics11040168	journal	April 2019
Building Predictive Models for Mechanism-of-Action Classification from Phenotypic Assay Data Sets Berg, Ellen L.; Yang, Jian; Polokoff, Mark A. Journal of Biomolecular Screening, Vol. 18, Issue 10 https://doi.org/10.1177/1087057113505324	journal	October 2013
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models Haselmayer, Philipp; Camps, Montserrat; Liu-Bujalski, Lesley The Journal of Immunology, Vol. 202, Issue 10 https://doi.org/10.4049/jimmunol.1800583	journal	April 2019
Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds Miyaura, Norio.; Suzuki, Akira. Chemical Reviews, Vol. 95, Issue 7 https://doi.org/10.1021/cr00039a007	journal	November 1995
Monodentate Phosphines Provide Highly Active Catalysts for Pd-Catalyzed CN Bond-Forming Reactions of Heteroaromatic Halides/Amines and (H)N-Heterocycles Anderson, Kevin W.; Tundel, Rachel E.; Ikawa, Takashi Angewandte Chemie International Edition, Vol. 45, Issue 39 https://doi.org/10.1002/anie.200601612	journal	October 2006
Defective B cell development and function in Btk-deficient mice Khan, Wasif N.; Alt, Frederick W.; Gerstein, Rachel M. Immunity, Vol. 3, Issue 3 https://doi.org/10.1016/1074-7613(95)90114-0	journal	September 1995
ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation Goess, Christian; Harris, Christopher M.; Murdock, Sara Modern Rheumatology, Vol. 29, Issue 3 https://doi.org/10.1080/14397595.2018.1484269	journal	July 2018
Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region Drabek, D.; Raguz, S.; De Wit, T. P. M. Proceedings of the National Academy of Sciences, Vol. 94, Issue 2 https://doi.org/10.1073/pnas.94.2.610	journal	January 1997
Mechanistic Investigations of Test Article–Induced Pancreatic Toxicity at the Endocrine–Exocrine Interface in the Rat Brenneman, Karrie A.; Ramaiah, Shashi K.; Rohde, Cynthia M. Toxicologic Pathology, Vol. 42, Issue 1 https://doi.org/10.1177/0192623313508851	journal	November 2013
Long-term therapy with sorafenib is associated with pancreatic atrophy Xu, Li; Zhou, Dong-Sheng; Zhao, Jing Journal of Surgical Research, Vol. 199, Issue 2 https://doi.org/10.1016/j.jss.2015.04.035	journal	December 2015
Bruton’s Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats Erickson, Rebecca I.; Schutt, Leah K.; Tarrant, Jacqueline M. Journal of Pharmacology and Experimental Therapeutics, Vol. 360, Issue 1 https://doi.org/10.1124/jpet.116.236224	journal	November 2016
Pancreatic Effects of a Bruton’s Tyrosine Kinase Small-molecule Inhibitor in Rats Are Strain-dependent Bhaskaran, Manoj; Cornwell, Paul D.; Sorden, Steven D. Toxicologic Pathology, Vol. 46, Issue 4 https://doi.org/10.1177/0192623318770163	journal	April 2018
Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy Liu, Lichuan; Di Paolo, Julie; Barbosa, Jim Journal of Pharmacology and Experimental Therapeutics, Vol. 338, Issue 1 https://doi.org/10.1124/jpet.111.181545	journal	April 2011
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases: Crystal Structures of Human BTK Kinase Domain Marcotte, Douglas J.; Liu, Yu-Ting; Arduini, Robert M. Protein Science, Vol. 19, Issue 3 https://doi.org/10.1002/pro.321	journal	January 2010
PHENIX: a comprehensive Python-based system for macromolecular structure solution Adams, Paul D.; Afonine, Pavel V.; Bunkóczi, Gábor Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 2, p. 213-221 https://doi.org/10.1107/S0907444909052925	journal	January 2010

Similar Records

Discovery of BIIB068: A Selective, Potent, Reversible Bruton?s Tyrosine Kinase Inhibitor as an Orall

Journal Article · Wed Jul 01 00:00:00 EDT 2020 · J. Med. Chem. · OSTI ID:1836743

Ma, Bin; Bohnert, Tonika; Otipoby, Kevin L.; +21 more

Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton?s Tyrosine Kinase

Journal Article · Sat Oct 01 00:00:00 EDT 2022 · J. Med. Chem. · OSTI ID:1836743

Tichenor, Mark S.; Wiener, John J.M.; Rao, Navin L.; +31 more

Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834

Journal Article · Sun Mar 01 00:00:00 EST 2015 · Bioorganic and Medicinal Chemistry Letters · OSTI ID:1836743

Young, Wendy B.; Barbosa, James; Blomgren, Peter; +25 more

Title: Discovery of BIIB068: A Selective, Potent, Reversible Bruton?s Tyrosine Kinase Inhibitor as an Orall

Citation Formats

References (56)

Similar Records

Related Subjects